文献速递病毒性肝炎

JNJ-64530440(新型衣壳组装调节剂)在初治慢性乙型肝炎病毒感染患者中为期4周单药治疗的安全性、抗病毒活性与药代动力学

Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection.
PubMed 文献 · J Antimicrob Chemother · 2022-01-01

这项1b期随机对照研究将20例初治HBeAg阳性或阴性慢性乙型肝炎患者按4:1随机分配至JNJ-64530440 750 mg每日一次、每日两次或安慰剂组,治疗28天。结果显示药物耐受良好,HBV DNA和RNA显著下降,药代动力学与健康志愿者相当。

要点

  • JNJ-64530440 750 mg每日一次或两次治疗28天耐受良好,不良事件多为轻中度。
  • 第29天HBV DNA较基线平均下降:每日一次组-3.2 log10 IU/mL,每日两次组-3.3 log10 IU/mL,安慰剂组0.1 log10 IU/mL。
  • 每日一次组5/8、每日两次组3/8患者HBV DNA低于定量下限。

核心结论

  • JNJ-64530440 750 mg每日一次或每日两次治疗28天耐受良好,在慢性乙型肝炎患者中实现了强效抗病毒活性。

研究设计与样本

  • 1b期随机对照试验(NCT03439488),20例初治HBeAg阳性或阴性慢性乙型肝炎患者按4:1随机分配至JNJ-64530440 750 mg每日一次、每日两次或安慰剂组,治疗28天。

主要发现

  • 所有患者(平均年龄43.8岁;85%男性;70%白人;20% HBeAg阳性)完成给药和28天随访。
  • 轻中度治疗中出现的不良事件发生于安慰剂组3/4、每日一次组6/8、每日两次组4/8患者,主要为乏力、丙氨酸氨基转移酶升高、中性粒细胞计数降低和头痛。
  • 第29天HBV DNA较基线平均(范围)变化:每日一次组-3.2(-2.4至-3.9)log10 IU/mL,每日两次组-3.3(-2.6至-4.1)log10 IU/mL,安慰剂组0.1(0.7至-0.6)log10 IU/mL。
  • HBV DNA低于定量下限者:每日一次组5/8,每日两次组3/8。
  • 基线HBV RNA可检测的患者中,第29天HBV RNA较基线平均(标准误)变化:每日一次组-2.65(0.81)log10 copies/mL,每日两次组-2.94(0.33)log10 copies/mL;HBV RNA为「目标未检出」者:每日一次组4/6,每日两次组3/7。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We investigated JNJ-64530440 (a hepatitis B virus capsid assembly modulator) safety, antiviral activity and pharmacokinetics in patients with chronic hepatitis B (CHB) (Phase 1b, NCT03439488). METHODS: Twenty treatment-naive, HBeAg-positive or -negative CHB patients were randomized 4:1 to JNJ-64530440 750 mg once or twice daily, or placebo for 28 days. RESULTS: All patients (mean age 43.8 years; 85% male; 70% White; 20% HBeAg positive) completed dosing/28 day follow-up. Mild-to-moderate treatment-emergent adverse events occurred in 3/4 (placebo), 6/8 (once-daily) and 4/8 (twice-daily) patients; mostly fatigue, increased alanine aminotransferase, decreased neutrophil count, and headache. Hepatitis B virus (HBV) DNA was substantially reduced; mean (range) changes from baseline at day 29 were: -3.2 (-2.4 to -3.9) (once-daily) and -3.3 (-2.6 to -4.1) (twice-daily) log10 IU/mL; placebo 0.1 (0.7 to -0.6) log10 IU/mL. HBV DNA levels were below the lower limit of quantification (LLOQ) in 5/8 (once-daily) and 3/8 (twice-daily) patients. For patients with detectable baseline HBV RNA, mean (SE) changes versus baseline in HBV RNA at day 29 were: -2.65 (0.81) (once-daily) and -2.94 (0.33) (twice-daily) log10 copies/mL. HBV RNA levels were 'target not detected' in 4/6 (once-daily) and 3/7 (twice-daily) patients. JNJ-64530440 pharmacokinetics in CHB patients were comparable with those in healthy volunteers. CONCLUSIONS: JNJ-64530440 750 mg once-daily or twice-daily for 28 days was well tolerated and achieved potent antiviral activity in CHB patients.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Gane EJ, Schwabe C, Berliba E, et al. Safety, antiviral activity and pharmacokinetics of JNJ-64530440, a novel capsid assembly modulator, as 4 week monotherapy in treatment-naive patients with chronic hepatitis B virus infection. J Antimicrob Chemother. 2022. PMID: 35040959. doi:10.1093/jac/dkab491

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。